RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Poulikos I. Poulikakos, Yogindra Persaud, Manickam Janakiraman, Xiangju Kong, Charles Ng, Gatien Moriceau, Hubing Shi, Mohammad Atefi, Bjoern Titz, May Tal Gabay, Maayan Salton, Kimberly B. Dahlman, Madhavi Tadi, Jennifer A. Wargo, Keith T. Flaherty, Mark C. Kelley, Tom Misteli, Paul B. Chapman, Jeffrey A. Sosman, Thomas G. Graeber, Antoni Ribas, Roger S. Lo, Neal Rosen and David B. Solit ()
Additional contact information
Poulikos I. Poulikakos: Memorial Sloan-Kettering Cancer Center
Yogindra Persaud: Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center
Manickam Janakiraman: Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center
Xiangju Kong: Jonsson Comprehensive Cancer Center, University of California at Los Angeles
Charles Ng: Jonsson Comprehensive Cancer Center, University of California at Los Angeles
Gatien Moriceau: Jonsson Comprehensive Cancer Center, University of California at Los Angeles
Hubing Shi: Jonsson Comprehensive Cancer Center, University of California at Los Angeles
Mohammad Atefi: Jonsson Comprehensive Cancer Center, University of California at Los Angeles
Bjoern Titz: Jonsson Comprehensive Cancer Center, University of California at Los Angeles
May Tal Gabay: Memorial Sloan-Kettering Cancer Center
Maayan Salton: National Cancer Institute, NIH
Kimberly B. Dahlman: Vanderbilt-Ingram Cancer Center
Madhavi Tadi: Memorial Sloan-Kettering Cancer Center
Jennifer A. Wargo: Massachusetts General Hospital Cancer Center
Keith T. Flaherty: Massachusetts General Hospital Cancer Center
Mark C. Kelley: Vanderbilt-Ingram Cancer Center
Tom Misteli: National Cancer Institute, NIH
Paul B. Chapman: Memorial Sloan-Kettering Cancer Center
Jeffrey A. Sosman: Vanderbilt-Ingram Cancer Center
Thomas G. Graeber: Jonsson Comprehensive Cancer Center, University of California at Los Angeles
Antoni Ribas: Jonsson Comprehensive Cancer Center, University of California at Los Angeles
Roger S. Lo: Jonsson Comprehensive Cancer Center, University of California at Los Angeles
Neal Rosen: Memorial Sloan-Kettering Cancer Center
David B. Solit: Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center

Nature, 2011, vol. 480, issue 7377, 387-390

Abstract: Although clinical trials have shown that RAF inhibitors prolong the survival of patients with BRAF-mutant melanoma, resistance inevitably develops; resistance is shown here to be frequently mediated by the expression of splicing variants of mutant BRAF.

Date: 2011
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/nature10662 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:480:y:2011:i:7377:d:10.1038_nature10662

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature10662

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().